vs
Side-by-side financial comparison of Magyar Bancorp, Inc. (MGYR) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
Protalix BioTherapeutics, Inc. is the larger business by last-quarter revenue ($9.1M vs $8.9M, roughly 1.0× Magyar Bancorp, Inc.). Magyar Bancorp, Inc. runs the higher net margin — 35.4% vs -60.3%, a 95.7% gap on every dollar of revenue. On growth, Magyar Bancorp, Inc. posted the faster year-over-year revenue change (19.0% vs -49.9%). Magyar Bancorp, Inc. produced more free cash flow last quarter ($3.7M vs $1.6M).
Magyar Bank is a bank based in New Brunswick, New Jersey with branches in Central Jersey.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
MGYR vs PLX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.9M | $9.1M |
| Net Profit | $3.1M | $-5.5M |
| Gross Margin | — | 49.4% |
| Operating Margin | 48.3% | -51.1% |
| Net Margin | 35.4% | -60.3% |
| Revenue YoY | 19.0% | -49.9% |
| Net Profit YoY | 50.4% | -184.8% |
| EPS (diluted) | $0.50 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $8.9M | $9.1M | ||
| Q3 25 | — | $17.9M | ||
| Q2 25 | — | $15.7M | ||
| Q1 25 | — | $10.1M | ||
| Q4 24 | — | $18.2M | ||
| Q3 24 | — | $18.0M | ||
| Q2 24 | $7.2M | $13.5M | ||
| Q1 24 | $7.5M | — |
| Q4 25 | $3.1M | $-5.5M | ||
| Q3 25 | — | $2.4M | ||
| Q2 25 | — | $164.0K | ||
| Q1 25 | — | $-3.6M | ||
| Q4 24 | — | $6.5M | ||
| Q3 24 | — | $3.2M | ||
| Q2 24 | $1.7M | $-2.2M | ||
| Q1 24 | $1.9M | — |
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
| Q4 25 | 48.3% | -51.1% | ||
| Q3 25 | — | 11.9% | ||
| Q2 25 | — | 7.5% | ||
| Q1 25 | — | -41.0% | ||
| Q4 24 | — | 39.6% | ||
| Q3 24 | — | 22.2% | ||
| Q2 24 | 30.5% | -18.0% | ||
| Q1 24 | 32.1% | — |
| Q4 25 | 35.4% | -60.3% | ||
| Q3 25 | — | 13.2% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | -35.8% | ||
| Q4 24 | — | 35.6% | ||
| Q3 24 | — | 18.0% | ||
| Q2 24 | 23.5% | -16.4% | ||
| Q1 24 | 25.1% | — |
| Q4 25 | $0.50 | $-0.06 | ||
| Q3 25 | — | $0.03 | ||
| Q2 25 | — | $0.00 | ||
| Q1 25 | — | $-0.05 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | — | $0.03 | ||
| Q2 24 | $0.27 | $-0.03 | ||
| Q1 24 | $0.30 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $34.1M | $14.7M |
| Total DebtLower is stronger | $49.1M | — |
| Stockholders' EquityBook value | $121.7M | $48.2M |
| Total Assets | $1.0B | $82.3M |
| Debt / EquityLower = less leverage | 0.40× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $34.1M | $14.7M | ||
| Q3 25 | — | $13.6M | ||
| Q2 25 | — | $17.9M | ||
| Q1 25 | — | $19.5M | ||
| Q4 24 | — | $19.8M | ||
| Q3 24 | — | $27.4M | ||
| Q2 24 | $49.0M | $23.4M | ||
| Q1 24 | $50.0M | — |
| Q4 25 | $49.1M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $121.7M | $48.2M | ||
| Q3 25 | — | $52.9M | ||
| Q2 25 | — | $49.9M | ||
| Q1 25 | — | $45.2M | ||
| Q4 24 | — | $43.2M | ||
| Q3 24 | — | $32.4M | ||
| Q2 24 | $109.0M | $28.6M | ||
| Q1 24 | $107.6M | — |
| Q4 25 | $1.0B | $82.3M | ||
| Q3 25 | — | $82.3M | ||
| Q2 25 | — | $78.5M | ||
| Q1 25 | — | $73.9M | ||
| Q4 24 | — | $73.4M | ||
| Q3 24 | — | $61.6M | ||
| Q2 24 | $944.4M | $91.5M | ||
| Q1 24 | $928.6M | — |
| Q4 25 | 0.40× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.7M | $2.0M |
| Free Cash FlowOCF − Capex | $3.7M | $1.6M |
| FCF MarginFCF / Revenue | 41.4% | 17.8% |
| Capex IntensityCapex / Revenue | 0.0% | 4.4% |
| Cash ConversionOCF / Net Profit | 1.17× | — |
| TTM Free Cash FlowTrailing 4 quarters | $8.7M | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.7M | $2.0M | ||
| Q3 25 | — | $-3.7M | ||
| Q2 25 | — | $-5.2M | ||
| Q1 25 | — | $-5.1M | ||
| Q4 24 | — | $4.0M | ||
| Q3 24 | — | $4.1M | ||
| Q2 24 | $1.7M | $-3.6M | ||
| Q1 24 | $553.0K | — |
| Q4 25 | $3.7M | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | $1.5M | $-3.8M | ||
| Q1 24 | $428.0K | — |
| Q4 25 | 41.4% | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | 21.5% | -28.1% | ||
| Q1 24 | 5.7% | — |
| Q4 25 | 0.0% | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | 2.0% | 1.3% | ||
| Q1 24 | 1.7% | — |
| Q4 25 | 1.17× | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | 1.00× | — | ||
| Q1 24 | 0.29× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MGYR
Segment breakdown not available.
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
